Zent2U is pleased to announce the successful finalization of the harmonized part of the registration procedure with European authorities for Apixaban 2,5mg and 5mg tablets. At the moment, national parts of the procedure have been pending in order to obtain Marketing Authorization across European countries. 🌍
Apixaban primary indication includes the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischemic attack (TIA), age 75 years or older, hypertension, heart failure, or diabetes mellitus. Additionally, Apixaban is prescribed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the prevention of recurrent DVT and PE in adults. 💊
Apixaban Zent2U is a generic alternative to the medication Eliquis® by Bristol Myers Squibb / Pfizer®.
We are pleased to provide our partners with this new generic product, enhancing their cardiovascular portfolio. 🤝
Partner up now and connect with our team today! 📧
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
Disclaimer: Apixaban which is subject to patent protection is currently not offered or made available in countries where patents are in force.
zent2u innovation HealthcareAdvancements embolism stroke thrombosis
